CN102657844A - 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 - Google Patents
长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 Download PDFInfo
- Publication number
- CN102657844A CN102657844A CN2012101160117A CN201210116011A CN102657844A CN 102657844 A CN102657844 A CN 102657844A CN 2012101160117 A CN2012101160117 A CN 2012101160117A CN 201210116011 A CN201210116011 A CN 201210116011A CN 102657844 A CN102657844 A CN 102657844A
- Authority
- CN
- China
- Prior art keywords
- ptx3
- virus
- mcmv
- mice
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title claims abstract description 183
- 230000003612 virological effect Effects 0.000 title claims abstract description 24
- 201000010099 disease Diseases 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title abstract description 158
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 title abstract description 158
- 230000002265 prevention Effects 0.000 title abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 56
- 230000004913 activation Effects 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 14
- 101710095468 Cyclase Proteins 0.000 claims description 31
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 206010022000 influenza Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 51
- 210000004443 dendritic cell Anatomy 0.000 description 46
- 208000015181 infectious disease Diseases 0.000 description 37
- 210000004072 lung Anatomy 0.000 description 24
- 102100037850 Interferon gamma Human genes 0.000 description 22
- 108010074328 Interferon-gamma Proteins 0.000 description 22
- 210000000952 spleen Anatomy 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 238000011725 BALB/c mouse Methods 0.000 description 14
- 241000701022 Cytomegalovirus Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000000822 natural killer cell Anatomy 0.000 description 14
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 13
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 102000006992 Interferon-alpha Human genes 0.000 description 12
- 108010047761 Interferon-alpha Proteins 0.000 description 12
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 12
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 12
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 12
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 10
- 238000012545 processing Methods 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 238000011740 C57BL/6 mouse Methods 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000002950 deficient Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 7
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 7
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 7
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 7
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 7
- 241000725643 Respiratory syncytial virus Species 0.000 description 7
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 7
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 201000002909 Aspergillosis Diseases 0.000 description 6
- 208000036641 Aspergillus infections Diseases 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100022297 Integrin alpha-X Human genes 0.000 description 6
- 102000013462 Interleukin-12 Human genes 0.000 description 6
- 108010065805 Interleukin-12 Proteins 0.000 description 6
- 102000002689 Toll-like receptor Human genes 0.000 description 6
- 108020000411 Toll-like receptor Proteins 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 6
- 229960002963 ganciclovir Drugs 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 241000712079 Measles morbillivirus Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000702670 Rotavirus Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000006041 cell recruitment Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000005022 packaging material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 210000003079 salivary gland Anatomy 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241001269238 Data Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 206010027906 Monocytosis Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000019836 digestive system infectious disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000531123 GB virus C Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 208000000785 Invasive Pulmonary Aspergillosis Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101150073530 Mptx1 gene Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 101100181106 Mus musculus Klra8 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241000724832 Non-A, non-B hepatitis virus Species 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 101150095640 PTX3 gene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 description 1
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GSTNAAOCEHQZDY-UHFFFAOYSA-N formic acid phosphane Chemical compound [PH4+].[O-]C=O GSTNAAOCEHQZDY-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- -1 inhalant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000006473 polyradiculopathy Diseases 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 208000019539 pyogenic bacterial infections due to MyD88 deficiency Diseases 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000023409 throat pain Diseases 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06004971A EP1832295A1 (en) | 2006-03-10 | 2006-03-10 | Use of PTX3 for the treatment of viral diseases |
EP06004971.5 | 2006-03-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800085614A Division CN101426516B (zh) | 2006-03-10 | 2007-02-28 | 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102657844A true CN102657844A (zh) | 2012-09-12 |
CN102657844B CN102657844B (zh) | 2014-03-26 |
Family
ID=37057312
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800085614A Expired - Fee Related CN101426516B (zh) | 2006-03-10 | 2007-02-28 | 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 |
CN201210116011.7A Expired - Fee Related CN102657844B (zh) | 2006-03-10 | 2007-02-28 | 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800085614A Expired - Fee Related CN101426516B (zh) | 2006-03-10 | 2007-02-28 | 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 |
Country Status (16)
Country | Link |
---|---|
US (2) | US7910092B2 (zh) |
EP (2) | EP1832295A1 (zh) |
JP (1) | JP5190605B2 (zh) |
KR (1) | KR101477781B1 (zh) |
CN (2) | CN101426516B (zh) |
AU (1) | AU2007224564B2 (zh) |
CA (1) | CA2646419C (zh) |
CY (1) | CY1115194T1 (zh) |
DK (1) | DK1993585T3 (zh) |
ES (1) | ES2475729T3 (zh) |
HK (2) | HK1129301A1 (zh) |
MX (1) | MX2008011413A (zh) |
PL (1) | PL1993585T3 (zh) |
PT (1) | PT1993585E (zh) |
SI (1) | SI1993585T1 (zh) |
WO (1) | WO2007104646A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652384A (zh) * | 2019-02-21 | 2019-04-19 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
CN114369150A (zh) * | 2022-01-24 | 2022-04-19 | 上海市儿科医学研究所 | Mptx2蛋白及其治疗耐甲氧西林金黄色葡萄球菌感染相关病症的应用 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
SI2012816T1 (sl) * | 2006-05-02 | 2012-09-28 | Sigma Tau Ind Farmaceuti | Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije |
PT2459721E (pt) * | 2009-07-29 | 2013-10-31 | Sigma Tau Ind Farmaceuti | Sistema de expressão melhorada da pentraxina 3 longa humana e suas utilizações |
WO2021230233A1 (ja) * | 2020-05-14 | 2021-11-18 | 学校法人日本医科大学 | 感染症の治療又は予防剤 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032516A2 (en) * | 1997-12-19 | 1999-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical compositions containing the long pentraxin ptx3 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW224053B (zh) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US6200952B1 (en) * | 1993-06-02 | 2001-03-13 | Sciclone Pharmaceuticals, Inc. | Combination therapy method for treating chronic hepatitis B |
WO1998018491A1 (en) | 1996-10-28 | 1998-05-07 | BURGSTINER, Jacqueline, Cook | Methods and compositions for dietary supplementation |
IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
ITRM20010294A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
US6872541B2 (en) * | 2001-07-25 | 2005-03-29 | Coulter International Corp. | Method and compositions for analysis of pentraxin receptors as indicators of disease |
ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
US20040137544A1 (en) * | 2002-10-31 | 2004-07-15 | Roberto Latini | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies |
ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
ITRM20040223A1 (it) * | 2004-05-07 | 2004-08-07 | Sigma Tau Ind Farmaceuti | Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi. |
ITRM20040489A1 (it) * | 2004-10-08 | 2005-01-08 | Sigma Tau Ind Farmaceuti | Pentraxina lunga ptx3 deglicosilata o desialidata. |
SI2012816T1 (sl) * | 2006-05-02 | 2012-09-28 | Sigma Tau Ind Farmaceuti | Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije |
-
2006
- 2006-03-10 EP EP06004971A patent/EP1832295A1/en not_active Withdrawn
-
2007
- 2007-02-28 WO PCT/EP2007/051889 patent/WO2007104646A2/en active Application Filing
- 2007-02-28 US US12/162,866 patent/US7910092B2/en not_active Expired - Fee Related
- 2007-02-28 JP JP2008558765A patent/JP5190605B2/ja not_active Expired - Fee Related
- 2007-02-28 CN CN2007800085614A patent/CN101426516B/zh not_active Expired - Fee Related
- 2007-02-28 DK DK07712377.6T patent/DK1993585T3/da active
- 2007-02-28 MX MX2008011413A patent/MX2008011413A/es active IP Right Grant
- 2007-02-28 PT PT77123776T patent/PT1993585E/pt unknown
- 2007-02-28 AU AU2007224564A patent/AU2007224564B2/en not_active Ceased
- 2007-02-28 EP EP07712377.6A patent/EP1993585B1/en active Active
- 2007-02-28 ES ES07712377.6T patent/ES2475729T3/es active Active
- 2007-02-28 CA CA2646419A patent/CA2646419C/en not_active Expired - Fee Related
- 2007-02-28 CN CN201210116011.7A patent/CN102657844B/zh not_active Expired - Fee Related
- 2007-02-28 SI SI200731474T patent/SI1993585T1/sl unknown
- 2007-02-28 PL PL07712377T patent/PL1993585T3/pl unknown
-
2008
- 2008-10-10 KR KR1020087024835A patent/KR101477781B1/ko not_active IP Right Cessation
-
2009
- 2009-07-24 HK HK09106827.7A patent/HK1129301A1/xx not_active IP Right Cessation
-
2011
- 2011-02-15 US US13/027,556 patent/US8268304B2/en not_active Expired - Fee Related
-
2013
- 2013-02-01 HK HK13101438.3A patent/HK1173983A1/zh not_active IP Right Cessation
-
2014
- 2014-06-23 CY CY20141100457T patent/CY1115194T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032516A2 (en) * | 1997-12-19 | 1999-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Pharmaceutical compositions containing the long pentraxin ptx3 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652384A (zh) * | 2019-02-21 | 2019-04-19 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
CN114369150A (zh) * | 2022-01-24 | 2022-04-19 | 上海市儿科医学研究所 | Mptx2蛋白及其治疗耐甲氧西林金黄色葡萄球菌感染相关病症的应用 |
CN114369150B (zh) * | 2022-01-24 | 2023-10-31 | 上海市儿科医学研究所 | Mptx2蛋白及其治疗耐甲氧西林金黄色葡萄球菌感染相关病症的应用 |
Also Published As
Publication number | Publication date |
---|---|
EP1832295A1 (en) | 2007-09-12 |
KR101477781B1 (ko) | 2014-12-30 |
PL1993585T3 (pl) | 2014-09-30 |
EP1993585B1 (en) | 2014-04-09 |
CN102657844B (zh) | 2014-03-26 |
US20090286726A1 (en) | 2009-11-19 |
SI1993585T1 (sl) | 2014-08-29 |
JP2009529563A (ja) | 2009-08-20 |
MX2008011413A (es) | 2008-12-15 |
KR20080104059A (ko) | 2008-11-28 |
EP1993585A2 (en) | 2008-11-26 |
AU2007224564B2 (en) | 2011-09-29 |
PT1993585E (pt) | 2014-07-11 |
HK1173983A1 (zh) | 2013-05-31 |
JP5190605B2 (ja) | 2013-04-24 |
HK1129301A1 (en) | 2009-11-27 |
US7910092B2 (en) | 2011-03-22 |
CA2646419A1 (en) | 2007-09-20 |
US20110224132A1 (en) | 2011-09-15 |
DK1993585T3 (da) | 2014-07-07 |
WO2007104646A3 (en) | 2007-11-15 |
CY1115194T1 (el) | 2017-01-04 |
CN101426516B (zh) | 2012-05-30 |
ES2475729T3 (es) | 2014-07-11 |
CN101426516A (zh) | 2009-05-06 |
WO2007104646A2 (en) | 2007-09-20 |
US8268304B2 (en) | 2012-09-18 |
AU2007224564A1 (en) | 2007-09-20 |
CA2646419C (en) | 2014-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101426516B (zh) | 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用 | |
Lang et al. | Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon‐I‐dependent manner in mice | |
CN101687033A (zh) | Cd200及其受体cd200r经破骨细胞分化调控骨量 | |
Rigden et al. | Macrophage phagocytosis of foot‐and‐mouth disease virus may create infectious carriers | |
US20230137667A1 (en) | Methods and compositions for treatment of coronavirus infection | |
CN101437535B (zh) | 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 | |
Greenan et al. | Advancing our understanding of corneal herpes simplex virus-1 immune evasion mechanisms and future therapeutics | |
Urbanska et al. | Spread of measles virus through axonal pathways into limbic structures in the brain of TAP1‐/‐mice | |
Giannandrea et al. | Memory CD8+ T cells are sufficient to alleviate impaired host resistance to influenza A virus infection caused by neonatal oxygen supplementation | |
CN102256611B (zh) | 使用含缺损基因组片段的病毒的抗病毒保护 | |
CN115252760B (zh) | 一种广谱抗冠状病毒的制剂及其制备方法 | |
Lu et al. | Inhibition of p21-activated kinase 1 attenuates the cardinal features of asthma through suppressing the lymph node homing of dendritic cells | |
Singh et al. | COVID-19: pathophysiology, transmission, and drug development for therapeutic treatment and vaccination strategies | |
Droebner et al. | The Alternative NF-κB Signalling Pathway is a Prerequisite for an Appropriate Immune Response Against Lymphocytic Choriomeningitis Virus Infection | |
Mufrrih | The unfolded protein response in Zika virus infection | |
Abilov et al. | IMPROVING THE TREATMENT OF CORONAVIRUS INFECTION COVID-19 | |
Jäkel | In vivo characterization of a pseudotyped vesicular stomatitis virus for the treatment of Hepatocellular carcinoma | |
Luo et al. | Autophagy induced by Cyprinid herpesvirus 3 (CyHV-3) facilitated intracellular viral replication and extracellular viral yields in common carp brain cells | |
Lamens | Defining the role of CD4+ T cells during human metapneumovirus infection | |
KR20230024280A (ko) | 바이러스 감염을 치료하기 위한 조성물 및 방법(compositions and methods for treating viral infections) | |
Lang | Innate immune functions during chronic infections | |
Singleton | B cell responses to respiratory viral infections | |
Azhar et al. | Opportunities and Challenges of Covid-19 Vaccine Production, A review | |
Liesman | Impact of the non-structural 2 protein on respiratory syncytial virus pathogenesis | |
Establish | Wild-Type Measles Virus Infection in Human |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. Free format text: FORMER OWNER: TECNOGEN S. P. A. Effective date: 20130308 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130308 Address after: Rome Italy Applicant after: Sigma-Tau Industrie Farmaceutiche Riunite S. P. A. Address before: Italy Caserta Applicant before: Tecnogen S. P. A. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1173983 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1173983 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 Termination date: 20190228 |
|
CF01 | Termination of patent right due to non-payment of annual fee |